Doctors have traditionally treated rheumatoid arthritis only after the disease becomes obvious.
By the time most patients receive a diagnosis, joint damage may already be underway. A new study suggests that this approach could eventually change.
Researchers from King’s College London have found that early treatment with a biologic drug can delay rheumatoid arthritis for years in people who are at high risk of developing the disease.
The findings were published in The Lancet Rheumatology and offer new hope that one day rheumatoid arthritis might be prevented or postponed before major symptoms appear.
Rheumatoid arthritis is a chronic inflammatory disease that affects the joints. Unlike ordinary wear-and-tear arthritis, rheumatoid arthritis occurs when the immune system mistakenly attacks the body’s own tissues.
The resulting inflammation causes pain, swelling, stiffness, and fatigue. Over time, the disease can damage joints permanently and affect many aspects of a person’s life.
Scientists now understand that rheumatoid arthritis does not begin overnight. Changes in the immune system can occur years before a person receives a diagnosis. Certain antibodies can often be detected in the blood long before joint damage becomes visible.
This discovery has encouraged researchers to investigate whether treating high-risk individuals early could alter the course of the disease.
To explore this possibility, researchers studied 213 people from the United Kingdom and the Netherlands who had signs that placed them at high risk of developing rheumatoid arthritis. Participants were randomly assigned to receive either abatacept or a placebo.
Abatacept is a biologic therapy already used to treat rheumatoid arthritis. It works by reducing specific immune system activities that contribute to inflammation and autoimmune disease.
Participants received treatment for one year. Researchers then continued following them for many years afterward. The extended follow-up period lasted between four and eight years, making this one of the longest prevention-focused studies ever conducted in rheumatoid arthritis.
The findings showed that early treatment made a meaningful difference. Participants who received abatacept developed rheumatoid arthritis significantly later than those who received placebo. In some individuals, the disease was delayed for several years after treatment had already stopped.
For patients, even a delay can be valuable. Rheumatoid arthritis often affects people during their working years. Pain, fatigue, and reduced mobility can make employment difficult and create financial challenges. Delaying disease onset may allow people to remain active, productive, and symptom-free for longer.
The study also showed that the drug worked best in those who faced the highest risk. Researchers identified these individuals using antibody tests. This finding suggests that future prevention strategies may be targeted toward people who are most likely to develop the disease.
Another encouraging result involved symptom improvement. During treatment, many participants experienced less joint pain, less fatigue, and better overall wellbeing. Although these benefits gradually diminished after treatment ended, they demonstrated that the immune system could be modified before full disease development.
Safety is always a major concern when treating people who do not yet have a disease. Fortunately, the researchers found that serious side effects occurred at similar rates in the treatment and placebo groups. No unexpected safety issues emerged during the long-term study period.
The results contribute to a growing movement in medicine that focuses on prevention rather than waiting for disease to appear. Similar approaches have already transformed the management of heart disease and some cancers. Researchers hope autoimmune diseases may eventually follow the same path.
Future studies will examine whether different treatment durations, combinations of therapies, or earlier intervention could further delay or perhaps even prevent rheumatoid arthritis altogether.
The most impressive aspect of this research is its long-term follow-up, which showed that benefits continued years after treatment stopped. The study demonstrates that rheumatoid arthritis can potentially be altered before diagnosis, challenging the traditional belief that treatment should begin only after symptoms become established.
However, the drug did not completely stop the disease, and more studies are needed to determine the most effective prevention strategy. Still, the findings represent an important step toward a future where autoimmune diseases may be managed before significant damage occurs.
If you care about pain, please read studies about how to manage your back pain, and Krill oil could improve muscle health in older people.
For more health information, please see recent studies about how to live pain-free with arthritis, and results showing common native American plant may help reduce diarrhea and pain.
Source: King’s College London.
